Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rosuvastatin Calcium

FDA-approved product (tablet, oral), marketed as Crestor, Ezallor Sprinkle, Rosuvastatin Calcium.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Rosuvastatin Calcium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atherosclerosis
  • Cardiovascular disease
  • Coronary artery disease
  • Familial hypercholesterolemia
  • Hypercholesterolemia
  • Hyperlipidemia
  • Hyperlipoproteinemia type 3

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hmg coa reductase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rosuvastatin Calcium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rosuvastatin Calcium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia

    NCT07619118 · start 2026-09-15

    Registered record
    Registry ID
    NCT07619118
    Conditions
    Hypercholesterolaemia
    Interventions
    laroprovstat/rosuvastatin 1; laroprovstat/rosuvastatin 2; laroprovstat/rosuvastatin 3; laroprovstat/rosuvastatin 4; Placebo to match laroprovstat/rosuvastatin 1,2,3; Placebo to match laroprovstat/rosuvastatin 4; Rosuvastatin 1; Rosuvastatin 2; Rosuvastatin 3; Rosuvastatin 4; Placebo to match Rosuvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-09-15
    Completion
    2027-05-28
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolaemia
    Interventionlaroprovstat/rosuvastatin 1; laroprovstat/rosuvastatin 2; laroprovstat/rosuvastatin 3; laroprovstat/rosuvastatin 4 +7 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • Polypills Approach for Multiple Cardiovascular Risk Factors

    NCT07679828 · start 2026-07-11

    Registered record
    Registry ID
    NCT07679828
    Conditions
    Hypertension; Dyslipidemia; Diabetes
    Interventions
    Fixed-Dose Combination Strategy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-07-11
    Completion
    2030-03-01
    Enrolment
    8,252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Dyslipidemia; Diabetes
    InterventionFixed-Dose Combination Strategy
    PhaseNot applicable
    Registry statusRecruiting

  • Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

    NCT07223671 · start 2025-12-31

    Registered record
    Registry ID
    NCT07223671
    Conditions
    Healthy Volunteers
    Interventions
    Repotrectinib; Metformin; Digoxin; Rosuvastatin; Bupropion; Flurbiprofen; Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-12-31
    Completion
    2026-03-19
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionRepotrectinib; Metformin; Digoxin; Rosuvastatin +3 more
    PhasePhase 1
    Registry statusCompleted

  • A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

    NCT07216482 · start 2025-11-11

    Registered record
    Registry ID
    NCT07216482
    Conditions
    Hyperlipidemia
    Interventions
    Enlicitide; Rosuvastatin; Placebo for Enlicitide; Placebo for Rosuvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2025-11-11
    Completion
    2026-11-05
    Enrolment
    996

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperlipidemia
    InterventionEnlicitide; Rosuvastatin; Placebo for Enlicitide; Placebo for Rosuvastatin
    PhasePhase 3
    Registry statusActive not recruiting

  • StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Randomized Controlled Trial

    NCT06785727 · start 2025-02-01

    Registered record
    Registry ID
    NCT06785727
    Conditions
    Ischemic Stroke; Transient Ischemic Attack
    Interventions
    Statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-02-01
    Completion
    2029-07-01
    Enrolment
    612

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Stroke; Transient Ischemic Attack
    InterventionStatin (atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin)
    PhasePhase 4
    Registry statusNot yet recruiting

  • Therapeutic Prospects of HMG-CoA Reductase Inhibitors, Atorvastatin and Rosuvastatin, in Osteoporotic Patients

    NCT07717788 · start 2025-02-01

    Registered record
    Registry ID
    NCT07717788
    Conditions
    Osteoporosis, Postmenopausal; Statin Therapy
    Interventions
    Alendronate 70 mg tablets; Atorvastatin; Rosuvastatin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-02-01
    Completion
    2026-07-01
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis, Postmenopausal; Statin Therapy
    InterventionAlendronate 70 mg tablets; Atorvastatin; Rosuvastatin
    PhaseNot applicable
    Registry statusCompleted

  • Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)

    NCT06231966 · start 2024-04-22

    Registered record
    Registry ID
    NCT06231966
    Conditions
    Peripheral Artery Disease; Polyvascular Disease
    Interventions
    Combination therapy of high-intensity dose rosuvastatin and ezetimibe; Rosuvastatin monotherapy for treat-to-target
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-04-22
    Completion
    2029-05-06
    Enrolment
    2,462

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral Artery Disease; Polyvascular Disease
    InterventionCombination therapy of high-intensity dose rosuvastatin and ezetimibe; Rosuvastatin monotherapy for treat-to-target
    PhaseNot applicable
    Registry statusRecruiting

  • ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

    NCT06293742 · start 2024-02-08

    Registered record
    Registry ID
    NCT06293742
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    ECC5004; Midazolam; Rosuvastatin; Digoxin; Atorvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-02-08
    Completion
    2024-04-15
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionECC5004; Midazolam; Rosuvastatin; Digoxin +1 more
    PhasePhase 1
    Registry statusCompleted

  • Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention

    NCT06186037 · start 2024-02-01

    Registered record
    Registry ID
    NCT06186037
    Conditions
    Coronary Artery Disease; Dyslipidemias; Primary Prevention
    Interventions
    Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg; Mono drug group of Rosuvastatin 20 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-02-01
    Completion
    2029-02-28
    Enrolment
    6,356

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Dyslipidemias; Primary Prevention
    InterventionCombination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg; Mono drug group of Rosuvastatin 20 mg
    PhasePhase 4
    Registry statusRecruiting

  • A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553

    NCT06105255 · start 2023-05-24

    Registered record
    Registry ID
    NCT06105255
    Conditions
    Healthy Male
    Interventions
    D-1553
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-05-24
    Completion
    2024-02-02
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Male
    InterventionD-1553
    PhasePhase 1
    Registry statusCompleted

  • Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome

    NCT05397405 · start 2022-05-23

    Registered record
    Registry ID
    NCT05397405
    Conditions
    Intracranial Artery Stenosis
    Interventions
    PCSK9 inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2022-05-23
    Completion
    2026-05-01
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntracranial Artery Stenosis
    InterventionPCSK9 inhibitor
    PhaseNot applicable
    Registry statusRecruiting

  • Fruquintinib DDI Study With P-gp and BCRP Substrates

    NCT05368805 · start 2022-03-02

    Registered record
    Registry ID
    NCT05368805
    Conditions
    Metastatic Colorectal Cancer
    Interventions
    Fruquintinib; Dabigatran Etexilate; Rosuvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-03-02
    Completion
    2022-04-22
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colorectal Cancer
    InterventionFruquintinib; Dabigatran Etexilate; Rosuvastatin
    PhasePhase 1
    Registry statusCompleted

  • Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)

    NCT05155137 · start 2021-12-20

    Registered record
    Registry ID
    NCT05155137
    Conditions
    Stroke; Cognitive Decline
    Interventions
    Drug Capsule (Valsartan + Amlodipine + Rosuvastatin); Stroke Riskometer
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2021-12-20
    Completion
    2030-12-14
    Enrolment
    8,518

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke; Cognitive Decline
    InterventionDrug Capsule (Valsartan + Amlodipine + Rosuvastatin); Stroke Riskometer
    PhasePhase 3
    Registry statusRecruiting

  • Effect of Statin Preloading in STEMI in Improving PCI Outcomes

    NCT04974814 · start 2021-05-26

    Registered record
    Registry ID
    NCT04974814
    Conditions
    ST Elevation Myocardial Infarction
    Interventions
    Rosuvastatin 40mg; Atorvastatin 80mg; Control Test
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-05-26
    Completion
    2023-04
    Enrolment
    99

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionST Elevation Myocardial Infarction
    InterventionRosuvastatin 40mg; Atorvastatin 80mg; Control Test
    PhaseNot applicable
    Registry statusUnknown

  • Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

    NCT04498741 · start 2020-07-08

    Registered record
    Registry ID
    NCT04498741
    Conditions
    RSV Infection
    Interventions
    EDP-938; EDP-938; EDP-938; Tacrolimus; Dabigatran; Rosuvastatin; EDP-938; Midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-07-08
    Completion
    2021-06-01
    Enrolment
    89

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRSV Infection
    InterventionEDP-938; EDP-938; EDP-938; Tacrolimus +4 more
    PhasePhase 1
    Registry statusCompleted